Digital image analysis outperforms manual biomarker assessment in breast cancer

Schnitt SJ, Lakhani SR, Anderson BO et al. Human cancers by organ site, breast cancer. In: Stewart BW, Wild C (eds). Chapter 5.2. World Cancer Report 2014, pp 508–526. Ellis, 2014, Tumours of the breast, 9 Goldhirsch, 2015, Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, Ann Oncol, 22, 1736, 10.1093/annonc/mdr304 Goldhirsch, 2015, Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Ann Oncol, 24, 2206, 10.1093/annonc/mdt303 Coates, 2015, Tailoring therapies - improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015, Ann Oncol, 26, 1533, 10.1093/annonc/mdv221 Guiu S, Michiels S, Andre F et al. Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol 201223:2997–3006. Parker, 2009, Supervised risk predictor of breast cancer based on intrinsic subtypes, J Clin Oncol, 27, 1160, 10.1200/JCO.2008.18.1370 Paquet, 2015, Absolute assignment of breast cancer intrinsic molecular subtype, J Natl Cancer Inst, 107, 357, 10.1093/jnci/dju357 Prat, 2013, Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer, J Clin Oncol, 31, 203, 10.1200/JCO.2012.43.4134 Sgroi, 2013, Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population, Lancet Oncol, 14, 1067, 10.1016/S1470-2045(13)70387-5 Bahreini, 2014, A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer, Breast Cancer, 22, 615, 10.1007/s12282-014-0528-0 Cheang, 2015, Defining breast cancer intrinsic subtypes by quantitative receptor expression, Oncologist, 20, 474, 10.1634/theoncologist.2014-0372 Polley, 2015, An international study to increase concordance in Ki67 scoring, Mod Pathol, 28, 778, 10.1038/modpathol.2015.38 Stalhammar, 2014, Low concordance of biomarkers in histopathological and cytological material from breast cancer, Histopathology, 64, 971, 10.1111/his.12344 Ekholm, 2014, Immunohistochemical assessment of Ki67 with antibodies SP6 and MIB1 in primary breast cancer: a comparison of prognostic value and reproducibility, Histopathology, 65, 252, 10.1111/his.12392 Christgen, 2015, The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer, Hum Pathol, 46, 1341, 10.1016/j.humpath.2015.05.016 Dowsett, 2011, Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group, J Natl Cancer Inst, 103, 1656, 10.1093/jnci/djr393 Grabau, 2014, Quality- and standardization document for breast tumors, Swedish Quality- and Standardization Committee (KVAST) tSPS, 1, 1 Romero, 2014, A novel model for Ki67 assessment in breast cancer, Diagn Pathol, 9, 118, 10.1186/1746-1596-9-118 Klintman, 2010, The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer, Mod Pathol, 23, 251, 10.1038/modpathol.2009.167 Reyal, 2013, Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma, PLoS One, 8, e55901, 10.1371/journal.pone.0055901 Hammond, 2010, American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer, J Clin Oncol, 28, 2784, 10.1200/JCO.2009.25.6529 Knutsvik, 2014, Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays, PLoS One, 9, e112121, 10.1371/journal.pone.0112121 Calza, 2006, Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients, Breast Cancer Res, 8, R34, 10.1186/bcr1517 Pawitan, 2005, Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts, Breast Cancer Res, 7, R953, 10.1186/bcr1325 Al Sarakbi, 2005, Is preoperative core biopsy accurate in determining the hormone receptor status in women with invasive breast cancer?, Int Semin Surg Oncol, 2, 15, 10.1186/1477-7800-2-15 Nadji, 2005, Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers, Am J Clin Pathol, 123, 21, 10.1309/4WV79N2GHJ3X1841 Cottu, 2008, Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer, Ann Oncol, 19, 595, 10.1093/annonc/mdn021 Yi, 2014, Which threshold for ER positivity? A retrospective study based on 9639 patients, Ann Oncol, 25, 1004, 10.1093/annonc/mdu053 Wolff, 2013, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update, J Clin Oncol, 31, 3997, 10.1200/JCO.2013.50.9984 Anders, 2015, HTSeq—a Python framework to work with high-throughput sequencing data, Bioinformatics, 31, 166, 10.1093/bioinformatics/btu638 Robinson, 2010, A scaling normalization method for differential expression analysis of RNA-seq data, Genome Biol, 11, R25, 10.1186/gb-2010-11-3-r25 Robinson, 2010, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data, Bioinformatics, 26, 139, 10.1093/bioinformatics/btp616 Cancer Genome Atlas Network, 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412 Eroles, 2012, Molecular biology in breast cancer: intrinsic subtypes and signaling pathways, Cancer Treat Rev, 38, 698, 10.1016/j.ctrv.2011.11.005 Tibshirani, 2002, Diagnosis of multiple cancer types by shrunken centroids of gene expression, Proc Natl Acad Sci USA, 99, 6567, 10.1073/pnas.082099299 Cleary, 2014, Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers, Nature, 508, 113, 10.1038/nature13187 Nguyen, 2015, Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells, Nature, 528, 267, 10.1038/nature15742 Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, 366, 883, 10.1056/NEJMoa1113205 Kårsnäs, 2015, A histopathological tool for quantification of biomarkers with sub-cellular resolution, Comput Methods Biomech Biomed Eng Imaging Vis, 3, 25, 10.1080/21681163.2014.885120 Holten-Rossing, 2015, Optimizing HER2 assessment in breast cancer: application of automated image analysis, Breast Cancer Res Treat, 152, 367, 10.1007/s10549-015-3475-3 Laurinaviciene, 2011, Membrane connectivity estimated by digital image analysis of HER2 immunohistochemistry is concordant with visual scoring and fluorescence in situ hybridization results: algorithm evaluation on breast cancer tissue microarrays, Diagn Pathol, 6, 87, 10.1186/1746-1596-6-87 Gavrielides, 2011, Observer variability in the interpretation of HER2/neu immunohistochemical expression with unaided and computer-aided digital microscopy, Arch Pathol Lab Med, 135, 233, 10.5858/135.2.233 Rizzardi, 2012, Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring, Diagn Pathol, 7, 42, 10.1186/1746-1596-7-42 Nielsen, 2013, Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma, Mod Pathol, 26, 404, 10.1038/modpathol.2012.188 Fitzgibbons, 2014, Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast, Arch Pathol Lab Med, 138, 595, 10.5858/arpa.2013-0566-CP Elston, 1991, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, 19, 403, 10.1111/j.1365-2559.1991.tb00229.x